Showing results (41-50 of 62) with videos related to
Sort By:
Pageof 7
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 14, 2010
Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasiaAndrew T Chan, Yoshifumi Baba, Kaori Shima, et al.Cancer & Metabolism|December 8, 2017
PKM2 is not required for colon cancer initiated by APC lossAllison N Lau, William J Israelsen, Jatin Roper, et al.Global Mental Health (Cambridge, England)|June 10, 2017
Developing a scalable training model in global mental health: pilot study of a video-assisted training Program for Generalist Clinicians in Rural NepalB Acharya, J Tenpa, M Basnet, et al.Plos One|October 4, 2011
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancerJatin Roper, Michael P Richardson, Wei Vivian Wang, et al.Disease Models & Mechanisms|April 19, 2014
Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human diseasePeter J Belmont, Eva Budinska, Ping Jiang, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 9, 2023
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b StudyWilliam J Sandborn, Silvio Danese, Jaroslaw Leszczyszyn, et al.Journal of Crohn'S & Colitis|December 23, 2023
Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative ColitisMina Hassan-Zahraee, Zhan Ye, Li Xi, et al.Cancer Letters|March 1, 2014
Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancerJatin Roper, Mark J Sinnamon, Erin M Coffee, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 14, 2021
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm StudySilvio Danese, Maria Klopocka, Ellen J Scherl, et al.Eclinicalmedicine|March 19, 2026
Once-daily oral ritlecitinib or brepocitinib versus placebo in patients with moderate-to-severely active Crohn's disease (PIZZICATO): an international, randomised, phase 2a trialSeverine Vermeire, Jessica R Allegretti, Hyo Jong Kim, et al.Pageof 7